Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis.

<h4>Background</h4>Giving patients anti-osteoporotic agents peri-operatively is a well-accepted strategy to increase fusion rate and prevent complications. The purpose of this study was to investigate effectiveness of teriparatide and bisphosphonate on fusion surgery of thoracic and lumb...

Full description

Bibliographic Details
Main Authors: Shih-Hao Cheng, Yi-Jie Kuo, Chiehfeng Chen, Yi-No Kang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0237566
_version_ 1818725904077029376
author Shih-Hao Cheng
Yi-Jie Kuo
Chiehfeng Chen
Yi-No Kang
author_facet Shih-Hao Cheng
Yi-Jie Kuo
Chiehfeng Chen
Yi-No Kang
author_sort Shih-Hao Cheng
collection DOAJ
description <h4>Background</h4>Giving patients anti-osteoporotic agents peri-operatively is a well-accepted strategy to increase fusion rate and prevent complications. The purpose of this study was to investigate effectiveness of teriparatide and bisphosphonate on fusion surgery of thoracic and lumbar spine.<h4>Methods</h4>We searched EMBASE and PubMed for randomized clinical trials (RCTs) and prospective comparative studies using teriparatide or bisphosphonate in peri-operative spinal fusion surgery. Our synthesized data of fusion rate, Oswestry disability index (ODI), and adverse event in contrast-based network meta-analysis. Pooled results were presented in risk ratio (RR) or mean difference (MD) with 95% confidence interval (CI).<h4>Results</h4>Our search hit eight RCTs and three prospective studies with 676 patients receiving spinal surgery. Pooled result showed that teriparatide+Denosumab leads to significantly higher fusion rate than placebo (RR, 2.84; 95% CI: 1.22 to 6.60) and bisphosphonate (RR, 2.59; 95% CI: 1.13 to 5.96). We did not observe significant finding among placebo, teriparatide, and bisphosphonate in the two network models.<h4>Conclusion</h4>This is the first network meta-analysis providing an overview of the use of teriparatide and bisphosphonate for spinal fusion surgery. Teriparatide treatments are worth to be consider for spinal fusion surgery.
first_indexed 2024-12-17T21:49:43Z
format Article
id doaj.art-23d53787ad5344b98706cd7dee1e56cd
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-17T21:49:43Z
publishDate 2020-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-23d53787ad5344b98706cd7dee1e56cd2022-12-21T21:31:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01159e023756610.1371/journal.pone.0237566Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis.Shih-Hao ChengYi-Jie KuoChiehfeng ChenYi-No Kang<h4>Background</h4>Giving patients anti-osteoporotic agents peri-operatively is a well-accepted strategy to increase fusion rate and prevent complications. The purpose of this study was to investigate effectiveness of teriparatide and bisphosphonate on fusion surgery of thoracic and lumbar spine.<h4>Methods</h4>We searched EMBASE and PubMed for randomized clinical trials (RCTs) and prospective comparative studies using teriparatide or bisphosphonate in peri-operative spinal fusion surgery. Our synthesized data of fusion rate, Oswestry disability index (ODI), and adverse event in contrast-based network meta-analysis. Pooled results were presented in risk ratio (RR) or mean difference (MD) with 95% confidence interval (CI).<h4>Results</h4>Our search hit eight RCTs and three prospective studies with 676 patients receiving spinal surgery. Pooled result showed that teriparatide+Denosumab leads to significantly higher fusion rate than placebo (RR, 2.84; 95% CI: 1.22 to 6.60) and bisphosphonate (RR, 2.59; 95% CI: 1.13 to 5.96). We did not observe significant finding among placebo, teriparatide, and bisphosphonate in the two network models.<h4>Conclusion</h4>This is the first network meta-analysis providing an overview of the use of teriparatide and bisphosphonate for spinal fusion surgery. Teriparatide treatments are worth to be consider for spinal fusion surgery.https://doi.org/10.1371/journal.pone.0237566
spellingShingle Shih-Hao Cheng
Yi-Jie Kuo
Chiehfeng Chen
Yi-No Kang
Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis.
PLoS ONE
title Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis.
title_full Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis.
title_fullStr Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis.
title_full_unstemmed Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis.
title_short Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis.
title_sort effects of teriparatide and bisphosphonate on spinal fusion procedure a systematic review and network meta analysis
url https://doi.org/10.1371/journal.pone.0237566
work_keys_str_mv AT shihhaocheng effectsofteriparatideandbisphosphonateonspinalfusionprocedureasystematicreviewandnetworkmetaanalysis
AT yijiekuo effectsofteriparatideandbisphosphonateonspinalfusionprocedureasystematicreviewandnetworkmetaanalysis
AT chiehfengchen effectsofteriparatideandbisphosphonateonspinalfusionprocedureasystematicreviewandnetworkmetaanalysis
AT yinokang effectsofteriparatideandbisphosphonateonspinalfusionprocedureasystematicreviewandnetworkmetaanalysis